Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

NCT05545124 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Donafenib + Tislelizumab

Sponsor

Henan Cancer Hospital